March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Evaluation Of Cytotoxicity Of Bevacizumab On VEGF-enriched Corneal Endothelial Cells
Author Affiliations & Notes
  • Carolee M. Cutler Peck
    Ophthalmology, University of Florida College of Medicine, Jacksonville, Florida
  • Raluca Rusovici
    Ophthalmology, University of Florida College of Medicine, Jacksonville, Florida
  • Sandeep Grover
    Ophthalmology, University of Florida College of Medicine, Jacksonville, Florida
  • K V. Chalam
    Ophthalmology, University of Florida College of Medicine, Jacksonville, Florida
  • Footnotes
    Commercial Relationships  Carolee M. Cutler Peck, None; Raluca Rusovici, None; Sandeep Grover, None; K. V. Chalam, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6002. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Carolee M. Cutler Peck, Raluca Rusovici, Sandeep Grover, K V. Chalam; Evaluation Of Cytotoxicity Of Bevacizumab On VEGF-enriched Corneal Endothelial Cells. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6002.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the cytotoxicity of varying doses of Bevacizumab on corneal endothelial cells in the presence of a range of concentrations of vascular endothelial growth factor (VEGF). Bevacizumab, a drug that neutralizes all isoforms of VEGF, is commonly used as an intracameral agent for the treatment of neovascularization of the iris and the angle. However, the safety of intracameral administration of bevacizumab and dose-dependent toxicity on corneal endothelial cells has not been established.

Methods: : Bovine corneal endothelial (BCE) cells were treated with VEGF (50 ng/ml) and/or bevacizumab (0.1-2 mg/ml) for 72h. Cytotoxicity in response to bevacizumab was evaluated by trypan blue exclusion, as well as Annexin V / Propidium Iodide (PI) staining. Cell proliferation was measured with the WST-1 assay. Morphological changes were recorded by brightfield microscopy of cells.

Results: : Bevacizumab was not cytotoxic at the concentrations tested and the percentage of bevacizumab-treated cells staining positively for both PI and Annexin V was less than 1%. The anti-proliferative effects of bevacizumab on BCE cells were dose-dependent; a dose of 1.5 mg/ml or 2 mg/ml produced a 33% (P=0.005) or 47% (P=0.001) decrease in cell proliferation compared to controls. Similar results were obtained in cells treated with a combination of bevacizumab and VEGF. VEGF (50 ng/ml) had no significant effect on cell proliferation compared to controls. Morphology of cells was unchanged after treatment with bevacizumab and/or VEGF compared to controls.

Conclusions: : Bevacizumab was safe and not toxic to BCE cells at concentrations commonly used in clinical practice as intracameral agent.

Keywords: cornea: endothelium • neovascularization • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×